We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




AI-Powered Cardiac Device Identifies Potential Heart Issues Before They Become Life-Threatening

By HospiMedica International staff writers
Posted on 15 Sep 2023

Nearly one-third of all heart attacks show no symptoms, and for over half of the people who suffer from cardiac-related fatalities, the first warning sign is the heart attack itself. More...

Unfortunately, most individuals don't seek medical help until they notice symptoms or actually experience a heart attack. Now, the world’s first early detection device for heart disease and other underlying cardiac issues is poised to revolutionize the field of cardiovascular care.

Forum Health (Flint, MI, USA) has rolled out its Multifunction Cardiogram (MCG) scan aimed at the early detection of heart disease and cardiac abnormalities. Designed as a preventive tool, the MCG scan is intended for both young and general populations who face an increased risk of heart disease. In contrast to traditional diagnostic approaches that wait for symptoms to appear, the MCG scan leverages cutting-edge artificial intelligence (AI) to identify a broad spectrum of heart-related issues. The system becomes more intelligent with each scan, making it the most thorough and precise heart assessment tool currently available.

Taking an MCG test is as simple as undergoing a 10-minute resting EKG, requiring no preparation from the patient. All the individual needs to do is lie still and relax while the device scans and gathers data about their heart. Specifically, the MCG evaluates how effectively blood is circulating into and out of the heart, as well as the overall health of the heart muscle. This collected data is then sent to a server where it's compared against a database featuring 200,000 patients with confirmed cardiovascular disease, as validated by angiograms. The MCG algorithm then gauges the patient's data against these established cases and produces an objective score ranging from 0 to 22 to measure heart dysfunction—the lower the score, the better the heart's condition. A detailed diagnostic report is then generated and shared securely with the attending physician. This report outlines whether the patient shows signs of local ischemia, global ischemia, or both, along with 26 other indicators of possible disease and inflammation.

"The MCG scan is a revolutionary cardiac device,” said Dr. Steven Meress, Forum Health Fond du Lac. “In March 2023, we performed the first round of scans; five months later, 12 out of 12 follow-up scans show improvement. This evidence shows how effective early interventions can be when based off the MCG scan and the positive impact on cardiac health."

Related Links:
Forum Health 


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Emergency Ventilator
Shangrila935
Ureteral Dilatation Balloon
Dornier Equinox
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.